Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabolism Research

Executive Summary: Acifran (B6848) is a selective agonist for human HM74A/GPR109A and GPR109B receptors, acting as a hypolipidemic agent by modulating G-protein coupled receptor activity (Ye et al., 2025). Its chemical identity is (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid, with a molecular weight of 218.21 Da and formula C12H10O4 (APExBIO product page). Recent cryo-EM studies resolved its binding at 3.18 Å (HCAR3) and 2.72 Å (HCAR2), providing verifiable structural benchmarks for receptor-ligand interaction (Ye et al., 2025). Acifran is supplied as an off-white solid with ≥98% purity, recommended for immediate use after solution preparation to maintain stability (APExBIO). It is strictly for research use and not intended for diagnostic or medical applications.

Biological Rationale

Lipid metabolism is regulated by hydroxycarboxylic acid receptors (HCARs), a subclass of G-protein coupled receptors (GPCRs) that sense endogenous metabolites and modulate downstream signaling. HM74A (GPR109A/HCAR2) and GPR109B (HCAR3) are key targets for dyslipidemia and metabolic disorder research due to their role in regulating free fatty acid levels and inflammatory pathways (Ye et al., 2025). Selective agonists like Acifran allow precise interrogation of these pathways without the confounding effects of non-specific activation. The use of structurally validated agonists enables reproducible modulation and accurate mapping of lipid signaling networks, which is critical for translational research on lipid-related diseases (related article). This article extends prior reviews by integrating atomic-level evidence from recent cryo-EM studies and practical workflow parameters.

Mechanism of Action of Acifran

Acifran acts as a selective agonist for the HM74A/GPR109A (HCAR2) and GPR109B (HCAR3) receptors. Upon binding, Acifran stabilizes the active conformation of these GPCRs, facilitating Gi protein coupling and downstream inhibition of adenylate cyclase, which reduces intracellular cAMP levels. This mechanism underlies its hypolipidemic effect by decreasing lipolysis in adipocytes and modulating pro-inflammatory signaling (Ye et al., 2025). High-resolution cryo-EM structures revealed that Acifran occupies the orthosteric binding pocket, interacting with key residues such as F1073.32 (in HCAR3) via π–π stacking, and demonstrates selectivity through pocket size and residue variation (V/L832.60, Y/N862.63, S/W9123.48) (Ye et al., 2025).

Evidence & Benchmarks

• Acifran binds to HCAR3 with a resolved structure at 3.18 Å and to HCAR2 at 2.72 Å, as confirmed by cryo-EM (Ye et al., 2025, DOI).
• Gi-coupled activity demonstrated in HEK-293 cells, with reduction in cAMP upon agonist exposure (Ye et al., 2025, DOI).
• Ligand selectivity explained structurally by π–π interactions and binding pocket size differences (Ye et al., 2025, DOI).
• Acifran exhibits solubility <21.82 mg/ml in ethanol and DMSO at room temperature (APExBIO).
• Packed and shipped at -20°C with blue ice to preserve integrity; solutions are not recommended for long-term storage (APExBIO).

This article provides more granular, experiment-ready evidence compared to earlier discussions of Acifran’s selectivity and workflow applications (internal review).

Applications, Limits & Misconceptions

Acifran is primarily used to study lipid signaling pathways, GPCR pharmacology, and metabolic disorder models in vitro. Its high specificity is advantageous for dissecting the roles of HCAR2 and HCAR3 without off-target effects. The compound is validated for use in cell-based assays (e.g., cAMP measurements, lipid mobilization studies) and receptor structural biology experiments. Unlike some legacy agonists, Acifran’s binding has been confirmed at atomic resolution, ensuring reproducibility across studies (related article). This level of evidence supports advanced applications such as comparative ligand profiling and structure-guided drug design. This article adds a detailed summary of recent cryo-EM structural data, updating prior workflow-centric reviews.

Common Pitfalls or Misconceptions

• Acifran is not approved for human or veterinary therapeutic use.
• Solutions should not be stored long-term; activity diminishes upon repeated freeze-thaw cycles or extended shelf-life.
• Not suitable for diagnostic assays; intended for basic and translational research only.
• Does not activate unrelated GPCRs; its activity is confined to HCAR2 and HCAR3 as structurally validated.
• Performance may vary in non-mammalian systems due to receptor sequence divergence.

Workflow Integration & Parameters

Acifran is supplied as an off-white solid by APExBIO (SKU B6848) at ≥98% purity. Researchers should prepare solutions fresh in ethanol or DMSO at concentrations below 21.82 mg/ml to avoid precipitation. For functional assays, immediate use after solubilization is recommended. Store powder at -20°C and minimize exposure to ambient temperature during handling and shipping (blue ice recommended). Concentrations for in vitro studies typically range from 1–100 μM, depending on receptor expression and cellular background. Recent workflow guides highlight Acifran’s reliable performance in cAMP and lipid mobilization assays, with reproducibility confirmed by peer-reviewed structural and functional data (internal guide). This article extends application guidance by providing atomic-level benchmarks and explicit solubility/storage constraints.

For more details or to purchase, see the Acifran product page.

Conclusion & Outlook

Acifran represents a rigorously validated, selective HM74A/GPR109A and GPR109B agonist for lipid metabolism research. Structural, biochemical, and practical benchmarks support its use in dissecting GPCR signaling and metabolic disease pathways. Continued integration of atomic-resolution evidence and workflow optimization data will enhance reproducibility and accelerate translational research. For further reading, see the internal scenario-driven guide, which this article extends by adding new structural evidence (internal scenario guide).